Regenerative Medicine, Delivered by You
Mesenchymal stromal cell therapy made practical
Gallant’s investigational therapies are designed for practicality— delivered ready-to-use, IV-administered, and backed by rigorous science as part of the FDA approval process. We put the potential of regenerative medicine into the hands of every veterinarian.
- Ethically sourced from healthy, FDA-qualified donor uterine tissue
- Easy intravenous administration with no special equipment or training
- Available when patients need it—off-the-shelf, no prep required
Regenerative Medicine Redefined
The old way (autologous) uses a patient’s own tissue, requiring surgical collection and processing before treatment.
Gallant’s new way (allogeneic) uses mesenchymal stromal cells from healthy donor tissue and is ready on-demand.
What’s in Development
Gallant is developing MSC therapies to target debilitating conditions. In addition to targeting clinical signs, our investigational products are designed to work at the source—modulating inflammation, supporting tissue repair, and offering new tools to support patient health and longevity.
Each therapy is progressing through the FDA’s approval process.
Built on Rigor. Backed by Progress.
Gallant’s development process follows FDA guidance for cell-based therapies, including rigorous clinical trials, safety reviews, and manufacturing controls. Every therapy is built with scientific rigor, transparency, and a commitment to patient care.
Our Science Library
Research, whitepapers & scientific perspective
Gallant contributes to the advancement of veterinary regenerative medicine with original research, peer-reviewed publications, and ongoing scientific dialogue. This library highlights our commitment to clinical rigor and transparent innovation.
Your Questions, Answered
We’ve compiled selected answers to the most common questions about stem cell therapy.
Don’t see your question in the list? View our Q&A page for vets.
Research shows that MSCs have the ability to migrate to areas of inflammation or tissue damage. Once there, they release various factors that help reduce inflammation and support the body’s natural healing processes. The benefits can vary depending on the specific disease and individual case.
There are no studies directly comparing stem cells to other therapies in the same population. The major difference between stem cells and other therapies is that most medications work to manage symptoms by reducing pain and inflammation. Stem cells are a potentially disease modifying therapy that work with the body’s cells to promote natural healing and repair.
The manufacturing facility adheres to current Good Manufacturing Practices (cGMP), which are the standards followed by drug manufacturers producing FDA-regulated products.
MSCs respond to signals from injured or diseased tissues, enabling them to migrate, or “home,” to the areas in the body where they are most needed. Because much of the immunomodulatory activity of MSCs occurs before they reach the target tissue, their therapeutic effects are thought to depend primarily on paracrine and systemic signaling rather than long-term tissue engraftment.
